ECTRIMS 2022 Symposium: The Burden of Cognitive Impairment in MS - European Medical Journal

ECTRIMS 2022 Symposium: The Burden of Cognitive Impairment in MS


This information is for Healthcare Professionals only.

This promotional video is organised and funded by Bristol Myers Squibb.

Click here for Prescribing Information

The Burden of Cognitive Impairment in MS, ECTRIMS 2022 BMS-promotional Symposium, highlights the importance of early awareness of cognitive impairment (CI), the impact to activities of daily living in patients with MS, the association of CI with MRI alterations and brain atrophy, as well as the results of early intervention with ozanimod to achieve brain preservation and delay CI.

Prof. Bruno Brochet discusses how CI can occur early in the course of MS, often before physical symptoms, can impact a large number of patients, and is an opportunity for early intervention.

Prof. Iris-Katharina Penner reviews the negative impact of CI on employment, the impact on driving ability and the need for assessments of fitness-to-drive, as well as the burden on activities of daily living including executive control, processing speed, new learning and memory.

Dr. Bianca Weinstock-Guttman provides an overview of the association of CI with MRI alterations and brain atrophy, demonstrating that deep gray matter (especially thalamic) atrophy is clearly associated with the risk of cognitive decline. She reviews how MS structural damage progression leads to CI, and finally demonstrates how advanced MRI imaging techniques showed a degree a correlation with CI.

The moderator, Prof. Hans-Peter Hartung, reviews of how early ozanimod use can provide benefits, especially in patients with preserved brain volume. Ozanimod can reduce MS relapses and up to 80% of patients continuously treated with ozanimod had low atrophy rates after 6 years.1,2

An interesting question and answer period wraps up the symposium.

IMM-GB-2300295 | Date of Prep: July 2023
Primary Endpoint Data
Safety and Tolerability Profile

Adverse events should be reported. Reporting forms and information can be found via:
Great Britain & Northern Ireland – The Yellow Card Scheme at: or search for MHRA Yellow Card in the Goggle Play or
Apple App store;
Ireland – HPRA Pharmacovigilance at
Adverse events should also be reported to Bristol-Myers Squibb via [email protected] or
08007311736 (Great Britain & Northern Ireland); 1 800 749 749 (Ireland).
  1. Brochet B, et al. Proportion of relapsing MS patients with low vs high annualized whole brain volume atrophy rates after 5–6 years of ozanimod and relationship to cognitive processing speed. Poster presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 26–28 October 2022; hybrid conference, Amsterdam, Netherlands.
  2. DeLuca, J., Arnold, D., Hartung, H. P., Kappos, L., Vaile, J., Cheng, C. Y., Pachai, C., Brochet, B. (2022). Positive Association Between Baseline Brain Volume and Long-term Cognition in Patients With Relapsing Multiple Sclerosis. Poster presented at the 8th European Academy of Neurology (EAN) Congress, Vienna, Austria, Jun 25 – 28, 2022. Available at!contentsessions/62231.

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally